Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. This article is intended to provide informational content and should not be viewed as an exhaustive an ...

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. This article is intended to provide informational content and should not be viewed as an exhaustive an ...

Goldman Sachs maintains a Neutral rating on NASDAQ:TGTX and raises the price target from $37 to $39.TG Therapeutics projects significant revenue growth, expecting FY25 revenue to reach approximately $616 million, an 87% increase, and FY26 revenue between $875 million and $900 million.BRIUMVI, the company's flagship product, is anticipated to generate substantial product revenue, contributing around $594 million in FY25 and between $825 million and $850 million in FY26.TG Therapeutics, Inc. (NASDAQ:TGTX) is ...

Key Takeaways TGTX shares rose after preliminary Q4 and full-year 2025 revenues topped company guidance.TGTX expects 2026 revenues of $875M to $900M, including $825M to $850M from U.S. Briumvi sales.TGTX plans multiple 2026 milestones, including ENHANCE data, subcutaneous Briumvi results, and azer-cel data.TG Therapeutics’ (TGTX) shares rose nearly 7% in after-hours trading, following the release of preliminary fourth-quarter and full-year 2025 results on Jan. 13, which beat expectations.TGTX issued bullish ...

U.S. stocks were lower, with the Nasdaq Composite falling more than 200 points on Wednesday.Shares of TG Therapeutics Inc (NASDAQ:TGTX) rose sharply during Wednesday's session after the company reported preliminary fiscal-year 2025 total global revenue results on Tuesday after the market closed.TG Therapeutics said preliminary total global revenue for full-year 2025 was approximately $616 million. The company reported preliminary U.S. net product revenue for BRIUMVI of approximately $182 million for the fou ...

市场整体表现与宏观数据 - 美国股指期货在周三盘前下跌 道指期货跌0.15% 标普500指数期货跌0.16% 纳斯达克100指数期货跌0.16% 罗素2000指数期货涨0.14% [1][3] - 主要ETF盘前走低 SPDR标普500 ETF信托(SPY)下跌0.15%至692.73美元 Invesco QQQ信托(QQQ)下跌0.20%至625.00美元 [3] - 前一交易日(周二)美股主要指数收跌 道指跌0.80%收于49,191.99点 标普500指数跌0.19%收于6,963.74点 纳斯达克综合指数跌0.10%收于23,709.87点 罗素2000指数跌0.098%收于2,633.10点 [9] - 12月消费者价格指数同比上涨2.7% 符合预期和前值 核心CPI同比上涨2.6% 略低于预期 [1] 重点公司动态 - 富国银行盘前下跌0.81% 市场预期其即将公布的季度营收为216.5亿美元 每股收益为1.67美元 [7] - 英国石油盘前下跌1.84% 公司宣布其能源转型业务面临高达50亿美元的资产减记 [7] - WeRide ADR盘前上涨1.59% 公司在腾讯微信上推出了Robotaxi小程序“WeRide Go” 允许用户在运营区域无需单独应用即可预订Robotaxi [7] - TG Therapeutics股价大涨6.99% 公司发布了第四季度初步营收预估 并对2026年给出了乐观展望 [13] - Gelteq股价飙升56.04% 公司报告其大麻素口服凝胶递送平台取得积极的临床前结果 [13] 行业与板块表现 - 周二交易时段 能源和必需消费品板块上涨 而金融和非必需消费品板块跌幅最大 [8] - 亚洲市场周三收盘涨跌互现 印度Nifty 50指数和中国沪深300指数下跌 澳大利亚ASX 200指数、日本日经225指数、香港恒生指数和韩国Kospi指数上涨 [17] - 欧洲市场早盘交易涨跌互现 [17] 大宗商品与加密货币 - 原油期货在纽约早盘交易中下跌0.98% 至每桶60.57美元附近 [16] - 黄金现货价格上涨0.93% 至每盎司4,629.12美元附近 其上一个历史高点为每盎司4,640.13美元 [16] - 比特币价格上涨3.32% 至每枚94,969.36美元 [16] 分析师观点与市场预期 - 分析师Jeremy Siegel预计2026年经济将表现强劲 受“强大的生产力激增”推动 他引用的第四季度GDP增长预估高达5.4% [10] - 该分析师对股市持“建设性但日益选择性”的看法 预计市场领导力将从估值已高的大型科技股转移 这些股票可能只有“温和涨幅” [10] - 他预计小盘股和非科技周期性股票将获得“两位数回报” 这些股票最有可能从预期的美联储降息中受益 [11] - 他建议投资者将投资组合从拥挤的美国科技股名称扩展到欧洲和日本 认为2026年将是“盈利增长而非估值扩张为投资者回报做出主要贡献”的一年 [11] 利率与政策焦点 - 市场关注美国最高法院可能就针对前总统特朗普关税权力的挑战做出裁决 [2] - 10年期美国国债收益率为4.17% 2年期美国国债收益率为3.52% [2] - 根据CME FedWatch工具 市场预计美联储在1月维持当前利率不变的可能性为97.2% [2] 即将发布的经济数据与事件 - 周三将发布延迟的11月美国零售销售和生产者价格指数数据(美东时间上午8:30) 以及延迟的10月美国商业库存和12月成屋销售数据(美东时间上午10:00) [14] - 多位美联储官员将发表讲话 包括亚特兰大联储主席博斯蒂克(美东时间中午12:00)、美联储理事米兰(美东时间中午12:30)、明尼阿波利斯联储主席卡什卡利(美东时间上午11:00)和纽约联储主席威廉姆斯(美东时间下午2:10) [14] - 美联储经济状况褐皮书将于美东时间下午2:00发布 [15]

With U.S. stock futures trading lower this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:Wall Street expects Bank of America Corp (NYSE:BAC) to report quarterly earnings at 96 cents per share on revenue of $27.87 billion before the opening bell, according to data from Benzinga Pro. Bank of America shares slipped 0.1% to $54.51 in after-hours trading.TG Therapeutics, Inc. (NASDAQ:TGTX) released its preliminary fourth quarter revenue estimates and provided an optim ...

Several biotechnology and pharmaceutical names posted notable gains in Tuesday's after-hours trading session, driven by corporate updates and investor enthusiasm around clinical and financial milestones.China SXT Pharmaceuticals, Inc. (SXTC) surged 17.40% to $0.12 after announcing the closing of a registered direct offering valued at about $10 million. Under the terms of the agreement, the company will sell 66,666,666 Class A ordinary shares, or pre-funded warrants in lieu thereof, at $0.15 per share to a ...

PresentationGood afternoon, everyone. Thanks for joining us for another session at the 44th JPMorgan Healthcare Conference. I'm Brian Cheng. I'm one of the senior biotech analysts here at the firm. On stage, we have Mike Weiss, who is the CEO of TG Therapeutics.Michael WeissChairman, CEO & President Great. Thank you, Brian, and thanks, everyone, for joining us. I'm going to get started here. Just before I do, let me just mention that I will make some forward-looking statements. For those of you who are inte ...

TG Therapeutics (NasdaqCM:TGTX) FY Conference January 13, 2026 04:30 PM ET Company ParticipantsMichael Weiss - CEOConference Call ParticipantsBrian Cheng - Senior Biotech AnalystBrian ChengGood afternoon, everyone. Thanks for joining us for another session at the 44th J.P. Morgan Healthcare Conference. I'm Brian Cheng. I'm one of the senior biotech analysts here at the firm. On stage, we have Mike Weiss, who is the CEO of TG Therapeutics. I'll now pass the mic to their CEO for a short presentation, followed ...